Neumora Therapeutics Inc

Neumora Therapeutics maintains a strong liquidity position, with a current ratio of 17.22, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $150.68 million, which is a substantial portion of its total assets of $404.47 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The company's profitability metrics are currently negative, with a return on equity (ROE) of -15.4% and a return on assets (ROA) of -14.51%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income and net income are both negative, at -$63.82 million and -$58.70 million, respectively, reflecting ongoing operational losses. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the company's operations are primarily focused on the development of therapeutics for respiratory and inflammatory conditions, which are key areas within the biotechnology and medical research industry. The company's exposure to these segments is likely to be significant, given its business model and product pipeline. The company's growth trajectory is currently constrained by its financial performance. The operating cash flow is negative at -$99.11 million, and the free cash flow is -$58.54 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The capital expenditure of -$775,000 suggests minimal investment in physical assets, which is typical for a biotechnology company in the development stage. The company's future growth will depend on its ability to advance its product pipeline and achieve regulatory approvals. The risk assessment for Neumora Therapeutics indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is currently unlevered. The dilution potential is low, as the number of shares outstanding is the same for both basic and diluted shares. The company's financial flexibility is supported by its strong cash position, which provides a buffer against short-term financial pressures. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's price targets from analysts range from $3.00 to $18.00, with a mean of $9.14 and a median of $8.00. The mean recommendation is 2.00, indicating a generally positive outlook from analysts, with 3 strong-buy, 4 buy, and 1 hold ratings. These analyst estimates suggest that the market sees potential for the company to improve its financial performance and achieve its development goals.